Omacetaxine Mepesuccinate
FDA-approved product (powder, subcutaneous), marketed as Synribo.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Cancer
- Neoplasm
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Other antineoplastic agents
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA59.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli37.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae36.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis53.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Omacetaxine Mepesuccinate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- PimozideExisting use: Psychosis, Tics, Tourette syndrome55.1% AI-predicted activityagainst E. coli15 registered studies
- VenetoclaxExisting use: Cancer, Chronic lymphocytic leukemia, Neoplasm55.0% AI-predicted activityagainst E. coli50+ registered studies
- RepotrectinibExisting use: Cancer, Neoplasm55.0% AI-predicted activityagainst E. coli17 registered studies
- Telotristat EtiprateExisting use: Carcinoid tumor, Diarrhea, Neuroendocrine neoplasm54.9% AI-predicted activityagainst E. coli27 registered studies
- Prasugrel HydrochlorideExisting use: Acute coronary syndrome, Hemorrhage, Intermediate coronary syndrome and 1 more54.8% AI-predicted activityagainst E. coli50+ registered studies
- Bosutinib MonohydrateExisting use: Chronic myelogenous leukemia, Myeloid leukemia54.6% AI-predicted activityagainst E. coli2 registered studies
- Ribociclib SuccinateExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 1 more54.5% AI-predicted activityagainst E. coli1 registered study
- Ergoloid MesylatesExisting use: Cardiovascular disease54.5% AI-predicted activityagainst E. coli2 registered studies
- CabotegravirExisting use: HIV infection, HIV-1 infection, Viral disease54.4% AI-predicted activityagainst E. coli50+ registered studies
- RisperidoneExisting use: Aggressive behavior, Autism, Bipolar disorder and 4 more54.2% AI-predicted activityagainst E. coli50+ registered studies
- LorlatinibExisting use: Cancer, Lymphoma, Neoplasm and 1 more54.1% AI-predicted activityagainst E. coli50+ registered studies
- TelaprevirExisting use: Chronic hepatitis C virus infection, Viral disease53.9% AI-predicted activityagainst E. coli50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Chidamide, Venetoclax, Azacitidine, and Homoharringtonine for High-risk Fit AML
NCT07643636 · start 2026-06-30
Registered record
- Registry ID
- NCT07643636
- Conditions
- AML (Acute Myeloid Leukemia)
- Interventions
- Chidamide (Chi)+VAH
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Not yet recruiting
- Start
- 2026-06-30
- Completion
- 2029-06-01
- Enrolment
- 46
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAML (Acute Myeloid Leukemia)InterventionChidamide (Chi)+VAHPhasePhase 2Registry statusNot yet recruitingHVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL).
NCT07517510 · start 2026-04-01
Registered record
- Registry ID
- NCT07517510
- Conditions
- Newly Diagnosed Mixed Phenotype Acute Leukemia (MPAL)
- Interventions
- HVA
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Enrolling by invitation
- Start
- 2026-04-01
- Completion
- 2027-12-31
- Enrolment
- 40
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNewly Diagnosed Mixed Phenotype Acute Leukemia (MPAL)InterventionHVAPhasePhase 2Registry statusEnrolling by invitationComparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy
NCT07651163 · start 2026-03-01
Registered record
- Registry ID
- NCT07651163
- Conditions
- Acute Myeloid Leukemia (AML); Lisaftoclax
- Interventions
- Lisaftoclax+daunorubicin+cytarabine; Lisaftoclax+homoharringtonine+cytarabine+aclarubicin; Lisaftoclax+azacitidine; Lisaftoclax+ cytarabine; Lisaftoclax+azacitidine or azacitidine
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Enrolling by invitation
- Start
- 2026-03-01
- Completion
- 2029-12
- Enrolment
- 450
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Myeloid Leukemia (AML); LisaftoclaxInterventionLisaftoclax+daunorubicin+cytarabine; Lisaftoclax+homoharringtonine+cytarabine+aclarubicin; Lisaftoclax+azacitidine; Lisaftoclax+ cytarabine +1 morePhasePhase 2 / Phase 3Registry statusEnrolling by invitationComparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy
NCT07651176 · start 2026-03-01
Registered record
- Registry ID
- NCT07651176
- Conditions
- Acute Myeloid Leukemia; Lisaftoclax
- Interventions
- Lisaftoclax+daunorubicin+cytarabine; Lisaftoclax+homoharringtonine+cytarabine+aclarubicin; Daunorubicin+cytarabine; Lisaftoclax+cytarabine; Lisaftoclax+azacitidine
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Enrolling by invitation
- Start
- 2026-03-01
- Completion
- 2029-12
- Enrolment
- 267
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Myeloid Leukemia; LisaftoclaxInterventionLisaftoclax+daunorubicin+cytarabine; Lisaftoclax+homoharringtonine+cytarabine+aclarubicin; Daunorubicin+cytarabine; Lisaftoclax+cytarabine +1 morePhasePhase 2 / Phase 3Registry statusEnrolling by invitationPre-DLI or Pro-DLI in Relapsed/Refractory Myeloid Neoplasms After HSCT
NCT07319793 · start 2026-01-01
Registered record
- Registry ID
- NCT07319793
- Conditions
- Acute Myeloid Leukemia; Myelodysplastic Syndromes (MDS)
- Interventions
- Prophylactic DLI; Preemptive DLI
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Not yet recruiting
- Start
- 2026-01-01
- Completion
- 2028-06-30
- Enrolment
- 200
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Myeloid Leukemia; Myelodysplastic Syndromes (MDS)InterventionProphylactic DLI; Preemptive DLIPhaseNot applicableRegistry statusNot yet recruitingAlternating Regimen of VA and Low-dose CHA in the Treatment of Unfit Newly Diagnosed AML
NCT07172204 · start 2025-09-16
Registered record
- Registry ID
- NCT07172204
- Conditions
- Intensive Chemotherapy Unfit; Newly Diagnosed Acute Myeloid Leukemia (AML); Age ≥60
- Interventions
- Alternately treated with VA/low CHA regimen
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2025-09-16
- Completion
- 2029-07-31
- Enrolment
- 25
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIntensive Chemotherapy Unfit; Newly Diagnosed Acute Myeloid Leukemia (AML); Age ≥60InterventionAlternately treated with VA/low CHA regimenPhasePhase 2Registry statusRecruitingEfficacy and Safety of VAH as a Bridging Regimen to Allo-HCT in Relapsed/Refractory AML
NCT07091006 · start 2025-08-01
Registered record
- Registry ID
- NCT07091006
- Conditions
- Relapse Leukemia
- Interventions
- VAH
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Not yet recruiting
- Start
- 2025-08-01
- Completion
- 2028-05-01
- Enrolment
- 44
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRelapse LeukemiaInterventionVAHPhasePhase 2Registry statusNot yet recruitingClinical Study on Neoadjuvant Therapy of Homoharringtonine Combined With Androgen Deprivation for Prostate Cancer
NCT06834321 · start 2025-03-19
Registered record
- Registry ID
- NCT06834321
- Conditions
- Prostate CA
- Interventions
- Homoharringtonine combined with androgen deprivation therapy; Placebo combined with androgen deprivation treatment group; radical prostatectomy
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2025-03-19
- Completion
- 2027-09-28
- Enrolment
- 96
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionProstate CAInterventionHomoharringtonine combined with androgen deprivation therapy; Placebo combined with androgen deprivation treatment group; radical prostatectomyPhasePhase 2Registry statusRecruitingNewly-diagnosed Pediatric T-cell ALL Protocol
NCT06855810 · start 2025-03-11
Registered record
- Registry ID
- NCT06855810
- Conditions
- Acute Lymphoblastic Leukemia; Childhood Leukemia, Acute Lymphoblastic; T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- Interventions
- Venetoclax; Dasatinib; homoharringtonine
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Recruiting
- Start
- 2025-03-11
- Completion
- 2031-06
- Enrolment
- 610
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Lymphoblastic Leukemia; Childhood Leukemia, Acute Lymphoblastic; T Cell Acute Lymphoblastic Leukemia/Lymphoblastic LymphomaInterventionVenetoclax; Dasatinib; homoharringtoninePhasePhase 2 / Phase 3Registry statusRecruitingHAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML
NCT06744556 · start 2025-01-21
Registered record
- Registry ID
- NCT06744556
- Conditions
- AML
- Interventions
- daunorubicin; Venetoclax; cytarabine; azacitidine; Homoharringtonine; Idarubicin
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Active not recruiting
- Start
- 2025-01-21
- Completion
- 2028-06-01
- Enrolment
- 41
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAMLInterventiondaunorubicin; Venetoclax; cytarabine; azacitidine +2 morePhasePhase 2Registry statusActive not recruitingCHG Combined With Venetoclax and Azacytidine in Newly Diagnosed AML
NCT06470841 · start 2024-09-20
Registered record
- Registry ID
- NCT06470841
- Conditions
- Acute Myeloid Leukemia
- Interventions
- CHG Combined With Venetoclax and Azacytidine
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Not yet recruiting
- Start
- 2024-09-20
- Completion
- 2028-12
- Enrolment
- 85
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Myeloid LeukemiaInterventionCHG Combined With Venetoclax and AzacytidinePhasePhase 2Registry statusNot yet recruitingIntermediate-dose HAD Regimen for CEBPA Double-mutated AML
NCT06529250 · start 2024-08-13
Registered record
- Registry ID
- NCT06529250
- Conditions
- AML
- Interventions
- HAD; Daunorubicin+Cytarabine
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Recruiting
- Start
- 2024-08-13
- Completion
- 2029-09-01
- Enrolment
- 148
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAMLInterventionHAD; Daunorubicin+CytarabinePhaseNot applicableRegistry statusRecruitingMRD-positive AML Clinical Study
NCT07131059 · start 2024-05-11
Registered record
- Registry ID
- NCT07131059
- Conditions
- AML, Adult
- Interventions
- Ivosidenib; Gilteritinib; Venetoclax; Avapritinib; Daunorubicin; Cytarabine; Idarubicin; Mitoxantrone; Homoharringtonine; Azacitidine; Ruxolitinib; Trametinib
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Recruiting
- Start
- 2024-05-11
- Completion
- 2028-10-30
- Enrolment
- 537
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAML, AdultInterventionIvosidenib; Gilteritinib; Venetoclax; Avapritinib +8 morePhaseNot applicableRegistry statusRecruitingComparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL
NCT06361329 · start 2024-04-03
Registered record
- Registry ID
- NCT06361329
- Conditions
- ETP-ALL
- Interventions
- Homoharringtonine; venetoclax; Cytarabine; G-CSF; Vindesine; Daunorubicin; cyclophosphamide; Dexamethasone; L-ASP
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Recruiting
- Start
- 2024-04-03
- Completion
- 2027-03-31
- Enrolment
- 81
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionETP-ALLInterventionHomoharringtonine; venetoclax; Cytarabine; G-CSF +5 morePhasePhase 3Registry statusRecruitingStudy of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients
NCT06394011 · start 2024-02-15
Registered record
- Registry ID
- NCT06394011
- Conditions
- Intermediate Risk Acute Myeloid Leukemia; High Risk Acute Myeloid Leukemia
- Interventions
- venetoclax, azacitidine and HAAG regimen
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Recruiting
- Start
- 2024-02-15
- Completion
- 2026-12-30
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionIntermediate Risk Acute Myeloid Leukemia; High Risk Acute Myeloid LeukemiaInterventionvenetoclax, azacitidine and HAAG regimenPhasePhase 2Registry statusRecruiting